當(dāng)前位置：首頁(yè) JCRQ2 期刊介紹(非官網(wǎng))

Pharmacoepidemiology And Drug SafetySCIE

國(guó)際簡(jiǎn)稱：PHARMACOEPIDEM DR S 參考譯名：藥物流行病學(xué)和藥物安全

中科院分區(qū)
4區(qū)
CiteScore分區(qū)
Q2
JCR分區(qū)
Q2

基本信息：: ISSN：1053-8569; E-ISSN：1099-1557; 是否OA：未開(kāi)放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：ENGLAND; 出版商：John Wiley and Sons Ltd; 出版語(yǔ)言：English; 出版周期：Bimonthly; 出版年份：1992; 研究方向：醫(yī)學(xué)-藥學(xué)

評(píng)價(jià)信息：: 影響因子：2.4; H-index：85; CiteScore指數(shù)：4.8; SJR指數(shù)：1.106; SNIP指數(shù)：1

發(fā)文數(shù)據(jù)：: Gold OA文章占比：31.52%; 研究類文章占比：89.05%; 年發(fā)文量：137; 自引率：0.0769...; 開(kāi)源占比：0.2218; 出版撤稿占比：0; 出版國(guó)人文章占比：0.02; OA被引用占比：0.1941...

投稿咨詢加急見(jiàn)刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見(jiàn)問(wèn)題

英文簡(jiǎn)介Pharmacoepidemiology And Drug Safety期刊介紹

The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.

Particular areas of interest include:

design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;

comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;

methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;

assessments of harm versus benefit in drug therapy;

patterns of drug utilization;

relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;

evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.

期刊簡(jiǎn)介Pharmacoepidemiology And Drug Safety期刊介紹

《Pharmacoepidemiology And Drug Safety》自1992出版以來(lái)，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見(jiàn)解，或?qū)彶槎嗄陙?lái)某個(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：約3月
醫(yī)學(xué)
PHARMACOLOGY & PHARMACY
SCIE
中科院4區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Pharmacoepidemiology And Drug Safety Cite Score數(shù)據(jù)

CiteScore：4.8
SJR：1.106
SNIP：1

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Pharmacology (medical)	Q2	105 / 272	61%
大類：Medicine 小類：Epidemiology	Q2	63 / 148	57%

CiteScore 是由Elsevier(愛(ài)思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過(guò)影響因子(IF)這一單一指標(biāo)來(lái)評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Pharmacoepidemiology And Drug Safety 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	4區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué) PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 公共衛(wèi)生、環(huán)境衛(wèi)生與職業(yè)衛(wèi)生	4區(qū) 4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開(kāi)始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Pharmacoepidemiology And Drug Safety JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q3	188 / 354	47%
學(xué)科：PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH	SCIE	Q2	163 / 403	59.7%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q3	192 / 354	45.9%
學(xué)科：PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH	SCIE	Q3	215 / 403	46.77%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問(wèn)題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
USA2091
England650
Denmark371
Netherlands368
Canada365
France252
GERMANY (FED REP GER)218
Sweden192
Spain169
Italy142

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Detection of drug safety signal of drug-induced neutropenia and agranulocytosis in all-aged patients using electronic medical records
Author: Sun, Cuicui; Zhao, Lixia; Yuan, Yujie; Xiang, Yanxiao; Liu, Anchang

Journal: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2023; Vol. 32, Issue 4, pp. 416-425. DOI: 10.1002/pds.5559
2、More extreme duplication in FDA Adverse Event Reporting System detected by literature reference normalization and fuzzy string matching
Author: Hung, Eric; Hauben, Manfred; Essex, Henry; Zou, Chen; Bright, Steve

Journal: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2023; Vol. 32, Issue 3, pp. 387-391. DOI: 10.1002/pds.5555
3、A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer
Author: Hidayat, Khemayanto; Zhou, Ying-Yi; Du, Hong-Zhen; Qin, Li-Qiang; Shi, Bi-Min; Li, Zeng-Ning

Journal: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2023; Vol. 32, Issue 2, pp. 107-125. DOI: 10.1002/pds.5550
4、Prescribed anti-glaucoma medication consumption and road traffic crash
Author: Lu, Li; Contrand, Benjamin; Schweitzer, Cedric; Gadegbeku, Blandine; Delcourt, Cecile; Lagarde, Emmanuel

Journal: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2023; Vol. 32, Issue 5, pp. 535-544. DOI: 10.1002/pds.5577
5、Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: A systematic review and meta-analysis.
Author: Jiang HY¹, Zhang X¹, Jiang CM², Fu HB³.

Journal: Pharmacoepidemiol Drug Saf. 2019 Mar;28(3):288-295. doi: 10.1002/pds.4716. Epub 2018 Dec 26.
6、Safety profile of traditional Chinese herbal injection: An analysis of a spontaneous reporting system in China.
Author: Li H^1,², Deng J³, Deng L³, Ren X², Xia J¹.

Journal: Pharmacoepidemiol Drug Saf. 2019 May 27. doi: 10.1002/pds.4805. [Epub ahead of print]
7、Association of prenatal exposure to acetaminophen and coffee with childhood asthma.
Author: Liu X, Liew Z, Olsen J, Pedersen LH, Bech BH, Agerbo E, Yuan W, Li J.

Journal: Pharmacoepidemiol Drug Saf. 2016 Feb;25(2):188-95. doi: 10.1002/pds.3940. Epub 2015 Dec 16.
8、Association between knowledge about levonorgestrel emergency contraception and the risk of ectopic pregnancy following levonorgestrel emergency contraception failure: a comparative survey.
Author: Zhang D, Yan MX, Ma J, Xia W, Xue RH, Sun J, Zhang J.

Journal: Pharmacoepidemiol Drug Saf. 2016 Jan 8. doi: 10.1002/pds.3946. [Epub ahead of print]